Trial Profile

A Phase 1b/2, Multicenter, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody-Drug Conjugate (ADC), in Combination With Atezolizumab With or Without Carboplatin as First-line Induction or Maintenance, in Subjects With Extensive-stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung03)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 24 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Ifinatamab deruxtecan (Primary) ; Carboplatin; Etoposide
Indications Small cell lung cancer
Focus Adverse reactions
Acronyms IDeate-Lung03
Sponsors Daiichi Sankyo Inc

13 Nov 2024 Planned primary completion date changed from 30 Nov 2026 to 30 Sep 2026.
17 Sep 2024 Trial design presented at the 49th European Society for Medical Oncology Congress.
04 Sep 2024 According to anDaiichi Sankyo media release, at WCLC 2024, an oral presentation will highlight efficacy and safety data from Part 1 of the DESTINY-Lung03 Phase Ib trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com